Understanding hereditary prostate cancer risk earlier
Around 10% of prostate cancers are hereditary. Men who carry related gene variants may have 5 to 7 times higher prostate cancer risk than average. Having one close relative with prostate cancer may increase risk by 2 to 3 times, and familial prostate cancer accounts for around 20% of all prostate cancers.
Genetic testing can help identify hereditary variants associated with prostate cancer, allowing doctors to discuss screening timing, frequency and ongoing health management based on individual risk.
What the Test Covers
The test covers 16 genes associated with hereditary prostate cancer: ATM, BRCA1, BRCA2, BRIP1, CHEK2, ELAC2, HOXB13, MLH1, MSH2, MSH5, MSH6, MSR1, PALB2, PTEN, RNASEL and SPOP. Results can support lifetime prostate cancer risk assessment.
Prostate cancer is not only a disease of older age. Men carrying prostate cancer-related variants may develop prostate cancer earlier. If a relevant variant is found, discuss annual screening and broader monitoring or treatment considerations with your doctor.
If You Are at Higher Risk
- Discuss whether prostate cancer screening should begin earlier.
- Consider more frequent screening according to individual risk, such as regular PSA testing or other appropriate checks.
- Pay attention to urinary symptoms, bone pain or other changes that may relate to prostate health.
- Discuss options that may help reduce risk or improve monitoring.
- Technical information indicates DNA sequencing 99.9%, SNP / indel variant calling >99%, and GenQA / UK NEQAS external quality assurance; variant classification may change as medical knowledge develops.
Enquire or Book
Contact the Well Clinic team to discuss whether this test may be suitable for you or your family.
Contact Us
WhatsApp / WeChat: +852 5292 0089
Address: Room B, 24/F, Lee Tung Building, 9 Li Yuen Street East, Central, Hong Kong